Certain peptides, like BPC-157, can cross the blood-brain barrier when administered nasally, allowing them to interact with neurotransmitters and reduce inflammation in the nervous system
Semaglutide also suppresses glucagon release, slows gastric emptying, and acts on appetite centers in the brain to promote satiety
If you want to turn patent data into a competitive advantage, you need to look at more than just the molecule patent. You need to look at the exclusivity stack. Using tools like DrugPatentWatch , we can see that Novo Nordisk has filed 320 U.S
Prolonged or high-dose use of BPC-157 may carry a theoretical risk of vascular proliferation in undesired tissues, particularly in individuals with cancer or pre-existing vascular disease. Perovic, D
If you experience dizziness, light-headedness, or fainting whilst taking GLP-1 therapy, contact your GP promptly for blood pressure assessment and potential medication adjustment